Gubra raised earnings guidance for full-year 2023. Organic revenue growth to be 25-28% compared to previous guidance of 16-21%. EBIT-margin excl.
special items to be 26-28% compared to previous guidance of Around 25%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
489 DKK | +6.30% |
|
+0.82% | +291.20% |
05-07 | Gubra A/S Announces Management Changes | CI |
04-17 | Gubra Unveils UCN2 as Novel Anti-Obesity Drug Candidate for Healthy Weight Loss | CI |
Gubra raised earnings guidance for full-year 2023. Organic revenue growth to be 25-28% compared to previous guidance of 16-21%. EBIT-margin excl.
special items to be 26-28% compared to previous guidance of Around 25%.
1st Jan change | Capi. | |
---|---|---|
+291.20% | 1.08B | |
+15.20% | 122B | |
+19.67% | 113B | |
+18.95% | 26.49B | |
-23.86% | 19.4B | |
-19.03% | 16.24B | |
-20.90% | 15.4B | |
-46.14% | 15.15B | |
+63.85% | 14.93B | |
+4.49% | 13.52B |